Rafati S - Search Results

1

Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

Doroud D, Rafati S. Doroud D, et al. Among authors: rafati s. Expert Rev Vaccines. 2012 Jan;11(1):69-86. doi: 10.1586/erv.11.166. Expert Rev Vaccines. 2012. PMID: 22149710 Free article. Review.

2

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S. Zadeh-Vakili A, et al. Among authors: rafati s. Vaccine. 2004 May 7;22(15-16):1930-40. doi: 10.1016/j.vaccine.2003.11.014. Vaccine. 2004. PMID: 15121305

3

Leishmaniasis vaccine candidates for development: a global overview.

Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Khamesipour A, et al. Among authors: rafati s. Indian J Med Res. 2006 Mar;123(3):423-38. Indian J Med Res. 2006. PMID: 16778321 Free article. Review.

4

Heat-shock proteins as powerful weapons in vaccine development.

Bolhassani A, Rafati S. Bolhassani A, et al. Among authors: rafati s. Expert Rev Vaccines. 2008 Oct;7(8):1185-99. doi: 10.1586/14760584.7.8.1185. Expert Rev Vaccines. 2008. PMID: 18844593 Free article. Review.

5

The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen.

Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. Bolhassani A, et al. Among authors: rafati s. Drug Deliv. 2009 May;16(4):196-204. doi: 10.1080/10717540902757721. Drug Deliv. 2009. PMID: 19514980 Free article.

6

Different spectra of therapeutic vaccine development against HPV infections.

Bolhassani A, Mohit E, Rafati S. Bolhassani A, et al. Among authors: rafati s. Hum Vaccin. 2009 Oct;5(10):671-89. doi: 10.4161/hv.5.10.9370. Epub 2009 Oct 28. Hum Vaccin. 2009. PMID: 19684468 Review.

7

Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S. Mizbani A, et al. Among authors: rafati s. Vaccine. 2009 Dec 10;28(1):53-62. doi: 10.1016/j.vaccine.2009.09.114. Epub 2009 Oct 8. Vaccine. 2009. PMID: 19818721

8

Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations.

Doroud D, Vatanara A, Zahedifard F, Gholami E, Vahabpour R, Rouholamini Najafabadi A, Rafati S. Doroud D, et al. Among authors: rafati s. J Pharm Pharm Sci. 2010;13(3):320-35. doi: 10.18433/j3r30t. J Pharm Pharm Sci. 2010. PMID: 21092706 Free article.

9

Improvement of different vaccine delivery systems for cancer therapy.

Bolhassani A, Safaiyan S, Rafati S. Bolhassani A, et al. Among authors: rafati s. Mol Cancer. 2011 Jan 7;10:3. doi: 10.1186/1476-4598-10-3. Mol Cancer. 2011. PMID: 21211062 Free PMC article. Review.

10

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.

Bolhassani A, Gholami E, Zahedifard F, Moradin N, Parsi P, Doustdari F, Seyed N, Papadopoulou B, Rafati S. Bolhassani A, et al. Among authors: rafati s. Exp Parasitol. 2011 May;128(1):9-17. doi: 10.1016/j.exppara.2011.01.012. Epub 2011 Jan 26. Exp Parasitol. 2011. PMID: 21276444

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters